Sumatriptan for the treatment of migraine attacks-a review of controlled clinical trials
Sumatriptan, a 5HT1-like receptor agonist, is a completely new treatment principle for migraine. In an extensive international programme of controlled clinical trials, sumatriptan, 6 mg subcutaneously and 100 mg orally, was superior to placebo in reducing headache and associated symptoms. The respon...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Tfelt-Hansen, Peer [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|
| Erschienen: |
USA/Oxford, UK: Blackwell Science Ltd ; 1993 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
Online-Ressource |
|---|
| Reproduktion: |
2002 ; Blackwell Publishing Journal Backfiles 1879-2005 |
|---|---|
| Übergeordnetes Werk: |
In: Cephalalgia - London [u.a.] : Sage, 1981, 13(1993), 4, Seite 0 |
| Übergeordnetes Werk: |
volume:13 ; year:1993 ; number:4 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1046/j.1468-2982.1993.1304238.x |
|---|
| Katalog-ID: |
NLEJ238586901 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ238586901 | ||
| 003 | DE-627 | ||
| 005 | 20230505184938.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 120417s1993 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1046/j.1468-2982.1993.1304238.x |2 doi | |
| 035 | |a (DE-627)NLEJ238586901 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 100 | 1 | |a Tfelt-Hansen, Peer |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sumatriptan for the treatment of migraine attacks-a review of controlled clinical trials |
| 264 | 1 | |a USA/Oxford, UK |b Blackwell Science Ltd |c 1993 | |
| 300 | |a Online-Ressource | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Sumatriptan, a 5HT1-like receptor agonist, is a completely new treatment principle for migraine. In an extensive international programme of controlled clinical trials, sumatriptan, 6 mg subcutaneously and 100 mg orally, was superior to placebo in reducing headache and associated symptoms. The response rate for subcutaneous sumatriptan (70–84% after 1 h and 81–87% after 2 h) was higher than for oral sumatriptan (50–67% after 2 h). Additional doses did not increase efficacy. Oral sumatriptan was superior to Cafergot (2 mg ergotamine plus 200 mg caffeine) and somewhat better than aspirin (900 mg) plus metoclopramide (10 mg). Recurrence of migraine occurred in approximately 40% of attacks. Side effects were generally mild and short-lived in the controlled clinical trials. However, in clinical practice sumatriptan has subsequently caused rare cases of heart ischemia and sumatriptan is contraindicated in patients with a history of ischemic heart disease. | ||
| 533 | |d 2002 |f Blackwell Publishing Journal Backfiles 1879-2005 |7 |2002|||||||||| | ||
| 650 | 4 | |a Controlled clinical trials | |
| 773 | 0 | 8 | |i In |t Cephalalgia |d London [u.a.] : Sage, 1981 |g 13(1993), 4, Seite 0 |h Online-Ressource |w (DE-627)NLEJ243926839 |w (DE-600)2019999-5 |x 1468-2982 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:1993 |g number:4 |g pages:0 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1046/j.1468-2982.1993.1304238.x |q text/html |x Verlag |z Deutschlandweit zugänglich |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-DJB | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 1993 |e 4 |h 0 | ||
| author_variant |
p t h pth |
|---|---|
| matchkey_str |
article:14682982:1993----::uarpafrhtetetfirietakaeiwfot |
| hierarchy_sort_str |
1993 |
| publishDate |
1993 |
| allfields |
10.1046/j.1468-2982.1993.1304238.x doi (DE-627)NLEJ238586901 DE-627 ger DE-627 rakwb Tfelt-Hansen, Peer verfasserin aut Sumatriptan for the treatment of migraine attacks-a review of controlled clinical trials USA/Oxford, UK Blackwell Science Ltd 1993 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Sumatriptan, a 5HT1-like receptor agonist, is a completely new treatment principle for migraine. In an extensive international programme of controlled clinical trials, sumatriptan, 6 mg subcutaneously and 100 mg orally, was superior to placebo in reducing headache and associated symptoms. The response rate for subcutaneous sumatriptan (70–84% after 1 h and 81–87% after 2 h) was higher than for oral sumatriptan (50–67% after 2 h). Additional doses did not increase efficacy. Oral sumatriptan was superior to Cafergot (2 mg ergotamine plus 200 mg caffeine) and somewhat better than aspirin (900 mg) plus metoclopramide (10 mg). Recurrence of migraine occurred in approximately 40% of attacks. Side effects were generally mild and short-lived in the controlled clinical trials. However, in clinical practice sumatriptan has subsequently caused rare cases of heart ischemia and sumatriptan is contraindicated in patients with a history of ischemic heart disease. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| Controlled clinical trials In Cephalalgia London [u.a.] : Sage, 1981 13(1993), 4, Seite 0 Online-Ressource (DE-627)NLEJ243926839 (DE-600)2019999-5 1468-2982 nnns volume:13 year:1993 number:4 pages:0 http://dx.doi.org/10.1046/j.1468-2982.1993.1304238.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 13 1993 4 0 |
| spelling |
10.1046/j.1468-2982.1993.1304238.x doi (DE-627)NLEJ238586901 DE-627 ger DE-627 rakwb Tfelt-Hansen, Peer verfasserin aut Sumatriptan for the treatment of migraine attacks-a review of controlled clinical trials USA/Oxford, UK Blackwell Science Ltd 1993 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Sumatriptan, a 5HT1-like receptor agonist, is a completely new treatment principle for migraine. In an extensive international programme of controlled clinical trials, sumatriptan, 6 mg subcutaneously and 100 mg orally, was superior to placebo in reducing headache and associated symptoms. The response rate for subcutaneous sumatriptan (70–84% after 1 h and 81–87% after 2 h) was higher than for oral sumatriptan (50–67% after 2 h). Additional doses did not increase efficacy. Oral sumatriptan was superior to Cafergot (2 mg ergotamine plus 200 mg caffeine) and somewhat better than aspirin (900 mg) plus metoclopramide (10 mg). Recurrence of migraine occurred in approximately 40% of attacks. Side effects were generally mild and short-lived in the controlled clinical trials. However, in clinical practice sumatriptan has subsequently caused rare cases of heart ischemia and sumatriptan is contraindicated in patients with a history of ischemic heart disease. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| Controlled clinical trials In Cephalalgia London [u.a.] : Sage, 1981 13(1993), 4, Seite 0 Online-Ressource (DE-627)NLEJ243926839 (DE-600)2019999-5 1468-2982 nnns volume:13 year:1993 number:4 pages:0 http://dx.doi.org/10.1046/j.1468-2982.1993.1304238.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 13 1993 4 0 |
| allfields_unstemmed |
10.1046/j.1468-2982.1993.1304238.x doi (DE-627)NLEJ238586901 DE-627 ger DE-627 rakwb Tfelt-Hansen, Peer verfasserin aut Sumatriptan for the treatment of migraine attacks-a review of controlled clinical trials USA/Oxford, UK Blackwell Science Ltd 1993 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Sumatriptan, a 5HT1-like receptor agonist, is a completely new treatment principle for migraine. In an extensive international programme of controlled clinical trials, sumatriptan, 6 mg subcutaneously and 100 mg orally, was superior to placebo in reducing headache and associated symptoms. The response rate for subcutaneous sumatriptan (70–84% after 1 h and 81–87% after 2 h) was higher than for oral sumatriptan (50–67% after 2 h). Additional doses did not increase efficacy. Oral sumatriptan was superior to Cafergot (2 mg ergotamine plus 200 mg caffeine) and somewhat better than aspirin (900 mg) plus metoclopramide (10 mg). Recurrence of migraine occurred in approximately 40% of attacks. Side effects were generally mild and short-lived in the controlled clinical trials. However, in clinical practice sumatriptan has subsequently caused rare cases of heart ischemia and sumatriptan is contraindicated in patients with a history of ischemic heart disease. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| Controlled clinical trials In Cephalalgia London [u.a.] : Sage, 1981 13(1993), 4, Seite 0 Online-Ressource (DE-627)NLEJ243926839 (DE-600)2019999-5 1468-2982 nnns volume:13 year:1993 number:4 pages:0 http://dx.doi.org/10.1046/j.1468-2982.1993.1304238.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 13 1993 4 0 |
| allfieldsGer |
10.1046/j.1468-2982.1993.1304238.x doi (DE-627)NLEJ238586901 DE-627 ger DE-627 rakwb Tfelt-Hansen, Peer verfasserin aut Sumatriptan for the treatment of migraine attacks-a review of controlled clinical trials USA/Oxford, UK Blackwell Science Ltd 1993 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Sumatriptan, a 5HT1-like receptor agonist, is a completely new treatment principle for migraine. In an extensive international programme of controlled clinical trials, sumatriptan, 6 mg subcutaneously and 100 mg orally, was superior to placebo in reducing headache and associated symptoms. The response rate for subcutaneous sumatriptan (70–84% after 1 h and 81–87% after 2 h) was higher than for oral sumatriptan (50–67% after 2 h). Additional doses did not increase efficacy. Oral sumatriptan was superior to Cafergot (2 mg ergotamine plus 200 mg caffeine) and somewhat better than aspirin (900 mg) plus metoclopramide (10 mg). Recurrence of migraine occurred in approximately 40% of attacks. Side effects were generally mild and short-lived in the controlled clinical trials. However, in clinical practice sumatriptan has subsequently caused rare cases of heart ischemia and sumatriptan is contraindicated in patients with a history of ischemic heart disease. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| Controlled clinical trials In Cephalalgia London [u.a.] : Sage, 1981 13(1993), 4, Seite 0 Online-Ressource (DE-627)NLEJ243926839 (DE-600)2019999-5 1468-2982 nnns volume:13 year:1993 number:4 pages:0 http://dx.doi.org/10.1046/j.1468-2982.1993.1304238.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 13 1993 4 0 |
| allfieldsSound |
10.1046/j.1468-2982.1993.1304238.x doi (DE-627)NLEJ238586901 DE-627 ger DE-627 rakwb Tfelt-Hansen, Peer verfasserin aut Sumatriptan for the treatment of migraine attacks-a review of controlled clinical trials USA/Oxford, UK Blackwell Science Ltd 1993 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Sumatriptan, a 5HT1-like receptor agonist, is a completely new treatment principle for migraine. In an extensive international programme of controlled clinical trials, sumatriptan, 6 mg subcutaneously and 100 mg orally, was superior to placebo in reducing headache and associated symptoms. The response rate for subcutaneous sumatriptan (70–84% after 1 h and 81–87% after 2 h) was higher than for oral sumatriptan (50–67% after 2 h). Additional doses did not increase efficacy. Oral sumatriptan was superior to Cafergot (2 mg ergotamine plus 200 mg caffeine) and somewhat better than aspirin (900 mg) plus metoclopramide (10 mg). Recurrence of migraine occurred in approximately 40% of attacks. Side effects were generally mild and short-lived in the controlled clinical trials. However, in clinical practice sumatriptan has subsequently caused rare cases of heart ischemia and sumatriptan is contraindicated in patients with a history of ischemic heart disease. 2002 Blackwell Publishing Journal Backfiles 1879-2005 |2002|||||||||| Controlled clinical trials In Cephalalgia London [u.a.] : Sage, 1981 13(1993), 4, Seite 0 Online-Ressource (DE-627)NLEJ243926839 (DE-600)2019999-5 1468-2982 nnns volume:13 year:1993 number:4 pages:0 http://dx.doi.org/10.1046/j.1468-2982.1993.1304238.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 13 1993 4 0 |
| source |
In Cephalalgia 13(1993), 4, Seite 0 volume:13 year:1993 number:4 pages:0 |
| sourceStr |
In Cephalalgia 13(1993), 4, Seite 0 volume:13 year:1993 number:4 pages:0 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Controlled clinical trials |
| isfreeaccess_bool |
false |
| container_title |
Cephalalgia |
| authorswithroles_txt_mv |
Tfelt-Hansen, Peer @@aut@@ |
| publishDateDaySort_date |
1993-01-01T00:00:00Z |
| hierarchy_top_id |
NLEJ243926839 |
| id |
NLEJ238586901 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ238586901</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505184938.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120417s1993 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1046/j.1468-2982.1993.1304238.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ238586901</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Tfelt-Hansen, Peer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Sumatriptan for the treatment of migraine attacks-a review of controlled clinical trials</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">USA/Oxford, UK</subfield><subfield code="b">Blackwell Science Ltd</subfield><subfield code="c">1993</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Sumatriptan, a 5HT1-like receptor agonist, is a completely new treatment principle for migraine. In an extensive international programme of controlled clinical trials, sumatriptan, 6 mg subcutaneously and 100 mg orally, was superior to placebo in reducing headache and associated symptoms. The response rate for subcutaneous sumatriptan (70–84% after 1 h and 81–87% after 2 h) was higher than for oral sumatriptan (50–67% after 2 h). Additional doses did not increase efficacy. Oral sumatriptan was superior to Cafergot (2 mg ergotamine plus 200 mg caffeine) and somewhat better than aspirin (900 mg) plus metoclopramide (10 mg). Recurrence of migraine occurred in approximately 40% of attacks. Side effects were generally mild and short-lived in the controlled clinical trials. However, in clinical practice sumatriptan has subsequently caused rare cases of heart ischemia and sumatriptan is contraindicated in patients with a history of ischemic heart disease.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2002</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2002||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Controlled clinical trials</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Cephalalgia</subfield><subfield code="d">London [u.a.] : Sage, 1981</subfield><subfield code="g">13(1993), 4, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243926839</subfield><subfield code="w">(DE-600)2019999-5</subfield><subfield code="x">1468-2982</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:1993</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1046/j.1468-2982.1993.1304238.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">1993</subfield><subfield code="e">4</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| series2 |
Blackwell Publishing Journal Backfiles 1879-2005 |
| author |
Tfelt-Hansen, Peer |
| spellingShingle |
Tfelt-Hansen, Peer misc Controlled clinical trials Sumatriptan for the treatment of migraine attacks-a review of controlled clinical trials |
| authorStr |
Tfelt-Hansen, Peer |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ243926839 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
NL |
| publishPlace |
USA/Oxford, UK |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1468-2982 |
| topic_title |
Sumatriptan for the treatment of migraine attacks-a review of controlled clinical trials Controlled clinical trials |
| publisher |
Blackwell Science Ltd |
| publisherStr |
Blackwell Science Ltd |
| topic |
misc Controlled clinical trials |
| topic_unstemmed |
misc Controlled clinical trials |
| topic_browse |
misc Controlled clinical trials |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| hierarchy_parent_title |
Cephalalgia |
| hierarchy_parent_id |
NLEJ243926839 |
| hierarchy_top_title |
Cephalalgia |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ243926839 (DE-600)2019999-5 |
| title |
Sumatriptan for the treatment of migraine attacks-a review of controlled clinical trials |
| ctrlnum |
(DE-627)NLEJ238586901 |
| title_full |
Sumatriptan for the treatment of migraine attacks-a review of controlled clinical trials |
| author_sort |
Tfelt-Hansen, Peer |
| journal |
Cephalalgia |
| journalStr |
Cephalalgia |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1993 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Tfelt-Hansen, Peer |
| container_volume |
13 |
| physical |
Online-Ressource |
| format_se |
Elektronische Aufsätze |
| author-letter |
Tfelt-Hansen, Peer |
| doi_str_mv |
10.1046/j.1468-2982.1993.1304238.x |
| title_sort |
sumatriptan for the treatment of migraine attacks-a review of controlled clinical trials |
| title_auth |
Sumatriptan for the treatment of migraine attacks-a review of controlled clinical trials |
| abstract |
Sumatriptan, a 5HT1-like receptor agonist, is a completely new treatment principle for migraine. In an extensive international programme of controlled clinical trials, sumatriptan, 6 mg subcutaneously and 100 mg orally, was superior to placebo in reducing headache and associated symptoms. The response rate for subcutaneous sumatriptan (70–84% after 1 h and 81–87% after 2 h) was higher than for oral sumatriptan (50–67% after 2 h). Additional doses did not increase efficacy. Oral sumatriptan was superior to Cafergot (2 mg ergotamine plus 200 mg caffeine) and somewhat better than aspirin (900 mg) plus metoclopramide (10 mg). Recurrence of migraine occurred in approximately 40% of attacks. Side effects were generally mild and short-lived in the controlled clinical trials. However, in clinical practice sumatriptan has subsequently caused rare cases of heart ischemia and sumatriptan is contraindicated in patients with a history of ischemic heart disease. |
| abstractGer |
Sumatriptan, a 5HT1-like receptor agonist, is a completely new treatment principle for migraine. In an extensive international programme of controlled clinical trials, sumatriptan, 6 mg subcutaneously and 100 mg orally, was superior to placebo in reducing headache and associated symptoms. The response rate for subcutaneous sumatriptan (70–84% after 1 h and 81–87% after 2 h) was higher than for oral sumatriptan (50–67% after 2 h). Additional doses did not increase efficacy. Oral sumatriptan was superior to Cafergot (2 mg ergotamine plus 200 mg caffeine) and somewhat better than aspirin (900 mg) plus metoclopramide (10 mg). Recurrence of migraine occurred in approximately 40% of attacks. Side effects were generally mild and short-lived in the controlled clinical trials. However, in clinical practice sumatriptan has subsequently caused rare cases of heart ischemia and sumatriptan is contraindicated in patients with a history of ischemic heart disease. |
| abstract_unstemmed |
Sumatriptan, a 5HT1-like receptor agonist, is a completely new treatment principle for migraine. In an extensive international programme of controlled clinical trials, sumatriptan, 6 mg subcutaneously and 100 mg orally, was superior to placebo in reducing headache and associated symptoms. The response rate for subcutaneous sumatriptan (70–84% after 1 h and 81–87% after 2 h) was higher than for oral sumatriptan (50–67% after 2 h). Additional doses did not increase efficacy. Oral sumatriptan was superior to Cafergot (2 mg ergotamine plus 200 mg caffeine) and somewhat better than aspirin (900 mg) plus metoclopramide (10 mg). Recurrence of migraine occurred in approximately 40% of attacks. Side effects were generally mild and short-lived in the controlled clinical trials. However, in clinical practice sumatriptan has subsequently caused rare cases of heart ischemia and sumatriptan is contraindicated in patients with a history of ischemic heart disease. |
| collection_details |
GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE |
| container_issue |
4 |
| title_short |
Sumatriptan for the treatment of migraine attacks-a review of controlled clinical trials |
| url |
http://dx.doi.org/10.1046/j.1468-2982.1993.1304238.x |
| remote_bool |
true |
| ppnlink |
NLEJ243926839 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1046/j.1468-2982.1993.1304238.x |
| up_date |
2024-07-06T05:30:26.362Z |
| _version_ |
1803806390475554816 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ238586901</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505184938.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120417s1993 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1046/j.1468-2982.1993.1304238.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ238586901</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Tfelt-Hansen, Peer</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Sumatriptan for the treatment of migraine attacks-a review of controlled clinical trials</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">USA/Oxford, UK</subfield><subfield code="b">Blackwell Science Ltd</subfield><subfield code="c">1993</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Sumatriptan, a 5HT1-like receptor agonist, is a completely new treatment principle for migraine. In an extensive international programme of controlled clinical trials, sumatriptan, 6 mg subcutaneously and 100 mg orally, was superior to placebo in reducing headache and associated symptoms. The response rate for subcutaneous sumatriptan (70–84% after 1 h and 81–87% after 2 h) was higher than for oral sumatriptan (50–67% after 2 h). Additional doses did not increase efficacy. Oral sumatriptan was superior to Cafergot (2 mg ergotamine plus 200 mg caffeine) and somewhat better than aspirin (900 mg) plus metoclopramide (10 mg). Recurrence of migraine occurred in approximately 40% of attacks. Side effects were generally mild and short-lived in the controlled clinical trials. However, in clinical practice sumatriptan has subsequently caused rare cases of heart ischemia and sumatriptan is contraindicated in patients with a history of ischemic heart disease.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2002</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2002||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Controlled clinical trials</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Cephalalgia</subfield><subfield code="d">London [u.a.] : Sage, 1981</subfield><subfield code="g">13(1993), 4, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243926839</subfield><subfield code="w">(DE-600)2019999-5</subfield><subfield code="x">1468-2982</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:1993</subfield><subfield code="g">number:4</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1046/j.1468-2982.1993.1304238.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">1993</subfield><subfield code="e">4</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.3993196 |